GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure

Patients with breast or ovarian cancer have not benefited from improved efficacy with pegylated liposomal doxorubicin relative to free drug, likely due to the limited extent of the enhanced permeability and retention (EPR) effect, further compromising drug bioavailability in the tumor. Herein it is...

ver descrição completa

Detalhes bibliográficos
Autor principal: Fonseca, Nuno A. (author)
Outros Autores: Gregório, Ana C. (author), Mendes, Vera M. (author), Lopes, Rui (author), Abreu, Teresa (author), Gonçalves, Nélio (author), Manadas, Bruno (author), Lacerda, Manuela (author), Figueiredo, Paulo (author), Pereira, Marta (author), Gaspar, Manuela (author), Colelli, Fabiana (author), Pesce, Daniela (author), Signorino, Giacomo (author), Focareta, Laura (author), Fucci, Alessandra (author), Cardile, Francesco (author), Pisano, Claudio (author), Cruz, Tony (author), Almeida, Luís (author), Moura, Vera (author), Simões, Sérgio (author), Moreira, João N. (author)
Formato: article
Idioma:eng
Publicado em: 2021
Assuntos:
Nucleolin
Targeted-drug delivery
Mesothelioma
Breast cancer
Nucleolin-overexpressing cancers
Texto completo:http://hdl.handle.net/10316/93834
País:Portugal
Oai:oai:estudogeral.sib.uc.pt:10316/93834

Texto Completo

http://hdl.handle.net/10316/93834

Registros relacionados